Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis

Objective Dysregulation of the blood–brain barrier (BBB) and transendothelial migration of immune cells are among the earliest central nervous system changes partaking in lesion formation in both multiple sclerosis (MS) and its early clinical form, the clinically isolated syndrome. Evidence for the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of neurology 2006-07, Vol.60 (1), p.45-55
Hauptverfasser: Ifergan, Igal, Wosik, Karolina, Cayrol, Romain, Kébir, Hania, Auger, Chantale, Bernard, Monique, Bouthillier, Alain, Moumdjian, Robert, Duquette, Pierre, Prat, Alexandre
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 55
container_issue 1
container_start_page 45
container_title Annals of neurology
container_volume 60
creator Ifergan, Igal
Wosik, Karolina
Cayrol, Romain
Kébir, Hania
Auger, Chantale
Bernard, Monique
Bouthillier, Alain
Moumdjian, Robert
Duquette, Pierre
Prat, Alexandre
description Objective Dysregulation of the blood–brain barrier (BBB) and transendothelial migration of immune cells are among the earliest central nervous system changes partaking in lesion formation in both multiple sclerosis (MS) and its early clinical form, the clinically isolated syndrome. Evidence for the anti‐inflammatory effects of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors within the central nervous system arose from studies demonstrating that statins improve clinical signs in the animal model of MS and reduce the number of gadolinium‐enhancing lesions in MS. Methods We sought to describe the impact of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor treatment on the physiology and immunology of human BBB‐derived endothelial cells (ECs). Results We demonstrate that lovastatin and simvastatin induce a 50 to 60% reduction in the diffusion rates of bovine serum albumin and [14C]‐sucrose across human BBB‐ECs in vitro through abrogation of isoprenylation processes, but independent of the expression of the tight junction molecules occludin, VE‐cadherin, JAM‐1, zonula occluden‐1, and zonula occluden‐2. Simvastatin and lovastatin were equipotent in reducing BBB permeability in vitro, with median effective concentration (EC50) of 9.5 × 10−8 and 1.0 × 10−7M, respectively. We further demonstrate that lovastatin and simvastatin treatment of BBB‐ECs significantly restricts the migration of clinically isolated syndrome–derived and MS‐derived monocytes and lymphocytes across the human BBB in vitro, through a specific reduction in the secretion of the chemokines monocyte chemotactic protein‐1/CCL2 and interferon‐γ–inducible protein‐10/CXCL10 by BBB‐ECs. Interpretation Our data parallel the previously reported magnetic resonance imaging–based radiological findings and suggest an effect of statins that could be beneficial in early MS, restricting the diffusion of molecular tracers and the migration of immune cells across the human BBB. Ann Neurol 2006
doi_str_mv 10.1002/ana.20875
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68707911</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68707911</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4575-66f29de7713fc51860d13df18a5df64b7c0e4164cc97cb6ef7f6c700a7270ba73</originalsourceid><addsrcrecordid>eNp1kMFu1DAQhi0EokvhwAsgX0DikNZOHDvhtlqVgliKREF7tCbOGEydZLGdln17THfbnjjNHL7_n9FHyEvOTjhj5SmMcFKyRtWPyILXFS-aUrSPyYJVUhQ1r8QReRbjL8ZYKzl7So64VGVbtnxBbi4TJDdGGrCfDdKf8wAj7fw09UUXwOUdQnAY6BbDgNA579KOwtjnREzBmUQ9zleT2SWkg_sRct00vqNf0eM1jLkyTXSYfXJbjzQaj2GKLj4nTyz4iC8O85h8f3_2bfWhWH85_7hargsjalUXUtqy7VEpXllT80aynle95Q3UvZWiU4ah4FIY0yrTSbTKSqMYA1Uq1oGqjsmbfe82TL_n_LEeXDToPYw4zVHLRjHVcp7Bt3vQ5P9iQKu3wQ0Qdpoz_c-yzpb1reXMvjqUzt2A_QN50JqB1wcAogFvQxbh4gOnWiHK26LTPXfjPO7-f1EvL5Z3p4t9wsWEf-4TEK60VFUmNxfnel1v5OfV5lJ_qv4CTBSlKA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68707911</pqid></control><display><type>article</type><title>Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Ifergan, Igal ; Wosik, Karolina ; Cayrol, Romain ; Kébir, Hania ; Auger, Chantale ; Bernard, Monique ; Bouthillier, Alain ; Moumdjian, Robert ; Duquette, Pierre ; Prat, Alexandre</creator><creatorcontrib>Ifergan, Igal ; Wosik, Karolina ; Cayrol, Romain ; Kébir, Hania ; Auger, Chantale ; Bernard, Monique ; Bouthillier, Alain ; Moumdjian, Robert ; Duquette, Pierre ; Prat, Alexandre</creatorcontrib><description>Objective Dysregulation of the blood–brain barrier (BBB) and transendothelial migration of immune cells are among the earliest central nervous system changes partaking in lesion formation in both multiple sclerosis (MS) and its early clinical form, the clinically isolated syndrome. Evidence for the anti‐inflammatory effects of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors within the central nervous system arose from studies demonstrating that statins improve clinical signs in the animal model of MS and reduce the number of gadolinium‐enhancing lesions in MS. Methods We sought to describe the impact of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor treatment on the physiology and immunology of human BBB‐derived endothelial cells (ECs). Results We demonstrate that lovastatin and simvastatin induce a 50 to 60% reduction in the diffusion rates of bovine serum albumin and [14C]‐sucrose across human BBB‐ECs in vitro through abrogation of isoprenylation processes, but independent of the expression of the tight junction molecules occludin, VE‐cadherin, JAM‐1, zonula occluden‐1, and zonula occluden‐2. Simvastatin and lovastatin were equipotent in reducing BBB permeability in vitro, with median effective concentration (EC50) of 9.5 × 10−8 and 1.0 × 10−7M, respectively. We further demonstrate that lovastatin and simvastatin treatment of BBB‐ECs significantly restricts the migration of clinically isolated syndrome–derived and MS‐derived monocytes and lymphocytes across the human BBB in vitro, through a specific reduction in the secretion of the chemokines monocyte chemotactic protein‐1/CCL2 and interferon‐γ–inducible protein‐10/CXCL10 by BBB‐ECs. Interpretation Our data parallel the previously reported magnetic resonance imaging–based radiological findings and suggest an effect of statins that could be beneficial in early MS, restricting the diffusion of molecular tracers and the migration of immune cells across the human BBB. Ann Neurol 2006</description><identifier>ISSN: 0364-5134</identifier><identifier>EISSN: 1531-8249</identifier><identifier>DOI: 10.1002/ana.20875</identifier><identifier>PMID: 16729291</identifier><identifier>CODEN: ANNED3</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Biological and medical sciences ; Blood-Brain Barrier - drug effects ; Blood-Brain Barrier - immunology ; Capillary Permeability - drug effects ; Capillary Permeability - immunology ; Cell Movement - immunology ; Cells, Cultured ; Chemokine CCL2 - metabolism ; Chemokine CCL2 - secretion ; Chemokine CXCL10 ; Chemokines, CXC - metabolism ; Chemokines, CXC - secretion ; Endothelial Cells - cytology ; Endothelial Cells - immunology ; Endothelial Cells - metabolism ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology ; Immunomodulators ; In Vitro Techniques ; Leukocytes - cytology ; Leukocytes - drug effects ; Leukocytes - secretion ; Lovastatin - pharmacology ; Male ; Medical sciences ; Membrane Proteins - metabolism ; Monocytes - cytology ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis - immunology ; Multiple Sclerosis - metabolism ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Neurology ; Occludin ; Pharmacology. Drug treatments ; Phosphoproteins - metabolism ; Protein Prenylation ; Simvastatin - pharmacology ; Tight Junctions - drug effects ; Tight Junctions - metabolism ; Zonula Occludens-1 Protein</subject><ispartof>Annals of neurology, 2006-07, Vol.60 (1), p.45-55</ispartof><rights>Copyright © 2006 American Neurological Association</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4575-66f29de7713fc51860d13df18a5df64b7c0e4164cc97cb6ef7f6c700a7270ba73</citedby><cites>FETCH-LOGICAL-c4575-66f29de7713fc51860d13df18a5df64b7c0e4164cc97cb6ef7f6c700a7270ba73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fana.20875$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fana.20875$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17944275$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16729291$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ifergan, Igal</creatorcontrib><creatorcontrib>Wosik, Karolina</creatorcontrib><creatorcontrib>Cayrol, Romain</creatorcontrib><creatorcontrib>Kébir, Hania</creatorcontrib><creatorcontrib>Auger, Chantale</creatorcontrib><creatorcontrib>Bernard, Monique</creatorcontrib><creatorcontrib>Bouthillier, Alain</creatorcontrib><creatorcontrib>Moumdjian, Robert</creatorcontrib><creatorcontrib>Duquette, Pierre</creatorcontrib><creatorcontrib>Prat, Alexandre</creatorcontrib><title>Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis</title><title>Annals of neurology</title><addtitle>Ann Neurol</addtitle><description>Objective Dysregulation of the blood–brain barrier (BBB) and transendothelial migration of immune cells are among the earliest central nervous system changes partaking in lesion formation in both multiple sclerosis (MS) and its early clinical form, the clinically isolated syndrome. Evidence for the anti‐inflammatory effects of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors within the central nervous system arose from studies demonstrating that statins improve clinical signs in the animal model of MS and reduce the number of gadolinium‐enhancing lesions in MS. Methods We sought to describe the impact of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor treatment on the physiology and immunology of human BBB‐derived endothelial cells (ECs). Results We demonstrate that lovastatin and simvastatin induce a 50 to 60% reduction in the diffusion rates of bovine serum albumin and [14C]‐sucrose across human BBB‐ECs in vitro through abrogation of isoprenylation processes, but independent of the expression of the tight junction molecules occludin, VE‐cadherin, JAM‐1, zonula occluden‐1, and zonula occluden‐2. Simvastatin and lovastatin were equipotent in reducing BBB permeability in vitro, with median effective concentration (EC50) of 9.5 × 10−8 and 1.0 × 10−7M, respectively. We further demonstrate that lovastatin and simvastatin treatment of BBB‐ECs significantly restricts the migration of clinically isolated syndrome–derived and MS‐derived monocytes and lymphocytes across the human BBB in vitro, through a specific reduction in the secretion of the chemokines monocyte chemotactic protein‐1/CCL2 and interferon‐γ–inducible protein‐10/CXCL10 by BBB‐ECs. Interpretation Our data parallel the previously reported magnetic resonance imaging–based radiological findings and suggest an effect of statins that could be beneficial in early MS, restricting the diffusion of molecular tracers and the migration of immune cells across the human BBB. Ann Neurol 2006</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Blood-Brain Barrier - drug effects</subject><subject>Blood-Brain Barrier - immunology</subject><subject>Capillary Permeability - drug effects</subject><subject>Capillary Permeability - immunology</subject><subject>Cell Movement - immunology</subject><subject>Cells, Cultured</subject><subject>Chemokine CCL2 - metabolism</subject><subject>Chemokine CCL2 - secretion</subject><subject>Chemokine CXCL10</subject><subject>Chemokines, CXC - metabolism</subject><subject>Chemokines, CXC - secretion</subject><subject>Endothelial Cells - cytology</subject><subject>Endothelial Cells - immunology</subject><subject>Endothelial Cells - metabolism</subject><subject>Female</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</subject><subject>Immunomodulators</subject><subject>In Vitro Techniques</subject><subject>Leukocytes - cytology</subject><subject>Leukocytes - drug effects</subject><subject>Leukocytes - secretion</subject><subject>Lovastatin - pharmacology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Membrane Proteins - metabolism</subject><subject>Monocytes - cytology</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis - immunology</subject><subject>Multiple Sclerosis - metabolism</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Neurology</subject><subject>Occludin</subject><subject>Pharmacology. Drug treatments</subject><subject>Phosphoproteins - metabolism</subject><subject>Protein Prenylation</subject><subject>Simvastatin - pharmacology</subject><subject>Tight Junctions - drug effects</subject><subject>Tight Junctions - metabolism</subject><subject>Zonula Occludens-1 Protein</subject><issn>0364-5134</issn><issn>1531-8249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMFu1DAQhi0EokvhwAsgX0DikNZOHDvhtlqVgliKREF7tCbOGEydZLGdln17THfbnjjNHL7_n9FHyEvOTjhj5SmMcFKyRtWPyILXFS-aUrSPyYJVUhQ1r8QReRbjL8ZYKzl7So64VGVbtnxBbi4TJDdGGrCfDdKf8wAj7fw09UUXwOUdQnAY6BbDgNA579KOwtjnREzBmUQ9zleT2SWkg_sRct00vqNf0eM1jLkyTXSYfXJbjzQaj2GKLj4nTyz4iC8O85h8f3_2bfWhWH85_7hargsjalUXUtqy7VEpXllT80aynle95Q3UvZWiU4ah4FIY0yrTSbTKSqMYA1Uq1oGqjsmbfe82TL_n_LEeXDToPYw4zVHLRjHVcp7Bt3vQ5P9iQKu3wQ0Qdpoz_c-yzpb1reXMvjqUzt2A_QN50JqB1wcAogFvQxbh4gOnWiHK26LTPXfjPO7-f1EvL5Z3p4t9wsWEf-4TEK60VFUmNxfnel1v5OfV5lJ_qv4CTBSlKA</recordid><startdate>200607</startdate><enddate>200607</enddate><creator>Ifergan, Igal</creator><creator>Wosik, Karolina</creator><creator>Cayrol, Romain</creator><creator>Kébir, Hania</creator><creator>Auger, Chantale</creator><creator>Bernard, Monique</creator><creator>Bouthillier, Alain</creator><creator>Moumdjian, Robert</creator><creator>Duquette, Pierre</creator><creator>Prat, Alexandre</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Willey-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200607</creationdate><title>Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis</title><author>Ifergan, Igal ; Wosik, Karolina ; Cayrol, Romain ; Kébir, Hania ; Auger, Chantale ; Bernard, Monique ; Bouthillier, Alain ; Moumdjian, Robert ; Duquette, Pierre ; Prat, Alexandre</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4575-66f29de7713fc51860d13df18a5df64b7c0e4164cc97cb6ef7f6c700a7270ba73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Blood-Brain Barrier - drug effects</topic><topic>Blood-Brain Barrier - immunology</topic><topic>Capillary Permeability - drug effects</topic><topic>Capillary Permeability - immunology</topic><topic>Cell Movement - immunology</topic><topic>Cells, Cultured</topic><topic>Chemokine CCL2 - metabolism</topic><topic>Chemokine CCL2 - secretion</topic><topic>Chemokine CXCL10</topic><topic>Chemokines, CXC - metabolism</topic><topic>Chemokines, CXC - secretion</topic><topic>Endothelial Cells - cytology</topic><topic>Endothelial Cells - immunology</topic><topic>Endothelial Cells - metabolism</topic><topic>Female</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</topic><topic>Immunomodulators</topic><topic>In Vitro Techniques</topic><topic>Leukocytes - cytology</topic><topic>Leukocytes - drug effects</topic><topic>Leukocytes - secretion</topic><topic>Lovastatin - pharmacology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Membrane Proteins - metabolism</topic><topic>Monocytes - cytology</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis - immunology</topic><topic>Multiple Sclerosis - metabolism</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Neurology</topic><topic>Occludin</topic><topic>Pharmacology. Drug treatments</topic><topic>Phosphoproteins - metabolism</topic><topic>Protein Prenylation</topic><topic>Simvastatin - pharmacology</topic><topic>Tight Junctions - drug effects</topic><topic>Tight Junctions - metabolism</topic><topic>Zonula Occludens-1 Protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ifergan, Igal</creatorcontrib><creatorcontrib>Wosik, Karolina</creatorcontrib><creatorcontrib>Cayrol, Romain</creatorcontrib><creatorcontrib>Kébir, Hania</creatorcontrib><creatorcontrib>Auger, Chantale</creatorcontrib><creatorcontrib>Bernard, Monique</creatorcontrib><creatorcontrib>Bouthillier, Alain</creatorcontrib><creatorcontrib>Moumdjian, Robert</creatorcontrib><creatorcontrib>Duquette, Pierre</creatorcontrib><creatorcontrib>Prat, Alexandre</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ifergan, Igal</au><au>Wosik, Karolina</au><au>Cayrol, Romain</au><au>Kébir, Hania</au><au>Auger, Chantale</au><au>Bernard, Monique</au><au>Bouthillier, Alain</au><au>Moumdjian, Robert</au><au>Duquette, Pierre</au><au>Prat, Alexandre</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis</atitle><jtitle>Annals of neurology</jtitle><addtitle>Ann Neurol</addtitle><date>2006-07</date><risdate>2006</risdate><volume>60</volume><issue>1</issue><spage>45</spage><epage>55</epage><pages>45-55</pages><issn>0364-5134</issn><eissn>1531-8249</eissn><coden>ANNED3</coden><abstract>Objective Dysregulation of the blood–brain barrier (BBB) and transendothelial migration of immune cells are among the earliest central nervous system changes partaking in lesion formation in both multiple sclerosis (MS) and its early clinical form, the clinically isolated syndrome. Evidence for the anti‐inflammatory effects of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors within the central nervous system arose from studies demonstrating that statins improve clinical signs in the animal model of MS and reduce the number of gadolinium‐enhancing lesions in MS. Methods We sought to describe the impact of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor treatment on the physiology and immunology of human BBB‐derived endothelial cells (ECs). Results We demonstrate that lovastatin and simvastatin induce a 50 to 60% reduction in the diffusion rates of bovine serum albumin and [14C]‐sucrose across human BBB‐ECs in vitro through abrogation of isoprenylation processes, but independent of the expression of the tight junction molecules occludin, VE‐cadherin, JAM‐1, zonula occluden‐1, and zonula occluden‐2. Simvastatin and lovastatin were equipotent in reducing BBB permeability in vitro, with median effective concentration (EC50) of 9.5 × 10−8 and 1.0 × 10−7M, respectively. We further demonstrate that lovastatin and simvastatin treatment of BBB‐ECs significantly restricts the migration of clinically isolated syndrome–derived and MS‐derived monocytes and lymphocytes across the human BBB in vitro, through a specific reduction in the secretion of the chemokines monocyte chemotactic protein‐1/CCL2 and interferon‐γ–inducible protein‐10/CXCL10 by BBB‐ECs. Interpretation Our data parallel the previously reported magnetic resonance imaging–based radiological findings and suggest an effect of statins that could be beneficial in early MS, restricting the diffusion of molecular tracers and the migration of immune cells across the human BBB. Ann Neurol 2006</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>16729291</pmid><doi>10.1002/ana.20875</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0364-5134
ispartof Annals of neurology, 2006-07, Vol.60 (1), p.45-55
issn 0364-5134
1531-8249
language eng
recordid cdi_proquest_miscellaneous_68707911
source MEDLINE; Access via Wiley Online Library
subjects Adult
Biological and medical sciences
Blood-Brain Barrier - drug effects
Blood-Brain Barrier - immunology
Capillary Permeability - drug effects
Capillary Permeability - immunology
Cell Movement - immunology
Cells, Cultured
Chemokine CCL2 - metabolism
Chemokine CCL2 - secretion
Chemokine CXCL10
Chemokines, CXC - metabolism
Chemokines, CXC - secretion
Endothelial Cells - cytology
Endothelial Cells - immunology
Endothelial Cells - metabolism
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
Immunomodulators
In Vitro Techniques
Leukocytes - cytology
Leukocytes - drug effects
Leukocytes - secretion
Lovastatin - pharmacology
Male
Medical sciences
Membrane Proteins - metabolism
Monocytes - cytology
Multiple Sclerosis - drug therapy
Multiple Sclerosis - immunology
Multiple Sclerosis - metabolism
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
Neurology
Occludin
Pharmacology. Drug treatments
Phosphoproteins - metabolism
Protein Prenylation
Simvastatin - pharmacology
Tight Junctions - drug effects
Tight Junctions - metabolism
Zonula Occludens-1 Protein
title Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T22%3A53%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Statins%20reduce%20human%20blood-brain%20barrier%20permeability%20and%20restrict%20leukocyte%20migration:%20Relevance%20to%20multiple%20sclerosis&rft.jtitle=Annals%20of%20neurology&rft.au=Ifergan,%20Igal&rft.date=2006-07&rft.volume=60&rft.issue=1&rft.spage=45&rft.epage=55&rft.pages=45-55&rft.issn=0364-5134&rft.eissn=1531-8249&rft.coden=ANNED3&rft_id=info:doi/10.1002/ana.20875&rft_dat=%3Cproquest_cross%3E68707911%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68707911&rft_id=info:pmid/16729291&rfr_iscdi=true